4 Healthcare Stock Stories For a Weekend Investment Checkup

Johnson & Johnson (NYSE:JNJ): Closing price $92.16

J&J’s Janssen Biotech, Inc. said Friday that the FDA has okayed Simponi Aria (golimumab) for infusion in the treatment of adults suffering from moderately to severely active rheumatoid arthritis in combination with methotrexate. The drug marks the sole fully-human anti-tumor necrosis factor-alpha infusible therapy, and has been shown to meaningfully improve signs and symptoms and physical function, and also inhibit the progression of structural damage. The Simponi Aria dose regimen is 2 mg/kg, given as an intravenous infusion at weeks 0 and 4, then every 8 weeks thereafter. The infusion is given over a 30-minute period, giving a short infusion time to patients.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

GlaxoSmithKline (NYSE:GSK): Closing price $52.15

GlaxoSmithKline has ordered its chief of emerging markets to China, so as to lead its response to the continuing crisis regarding alleged bribery and corruption, said an inside source on Friday, who added that Chief Executive Andrew Witty has sent GSK President Emerging Markets Abbas Hussain, along with the group’s chief of internal audit and a senior legal official. The drug maker has also recruited the auditors Ernst & Young to conduct an independent review of its systems in China following the scandal, according to another source on Wednesday.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

VIVUS, Inc. (NASDAQ:VVUS): Closing price $13.67

The owner-managed and operated investment advisory firm First Manhattan Co., which owns roughly 9.9 percent of the outstanding shares of VIVUS, and Sarissa Capital Management LP, which is a registered investment adviser that owns around 2 percent of VIVUS’s outstanding shares, jointly announced on Friday that VIVUS and FMC have reached a resolution concerning their proxy contest related to the Company’s 2013 Annual Meeting of Stockholders. Through the terms of the accord, Charles J. Casamento Ernest Mario, Ph. D., Linda M. Shortliffe, M.D., Peter Y. Tam, and Leland F. Wilson will resign from the board effective on Saturday. Beyond that, Anthony P. Zook is expected to be appointed VIVUS’s new chief executive, and also appointed to the board.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Biogen IDEC (NASDAQ:BIIB): Closing price $230.45

On Friday, Biogen announced that regulatory authorities in the United States and the European Union have accepted the marketing applications for the review of Plegridy (peginterferon beta-1a), which is the firm’s pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis. The FDA has accepted Biogen IDEC’s Biologics License Application for marketing approval of Plegridy in the United States, and allowed the company a standard review timeline. Also, the marketing authorization application of Plegrdiy for review in the European Union was validated by the European Medicines Agency.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

Don’t Miss: Can Merck Finally Get Past the Vioxx Scandal?